Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis

BACKGROUND: SARS-CoV-2 vaccine responses that could harbor potential risks to chronic liver diseased patients. AIMS: To assess immune response following Pfizer's SARS-CoV-2 vaccine in patients with different liver fibrosis severities of nonalcoholic fatty liver disease (NAFLD). METHODS: Clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Hakimian, David, Amer, Johnny, Jammal, Alaa, Shafrir, Asher, Milgrom, Yael, Masarowah, Mohammad, Hazou, Wadi, Ishay, Yuval, Imam, Ashraf, Francis, Adi, Khalaileh, Abed, Safadi, Rifaat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Regular paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598407/
https://www.ncbi.nlm.nih.gov/pubmed/37885772
http://dx.doi.org/10.1016/j.jvacx.2023.100359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598407/
https://www.ncbi.nlm.nih.gov/pubmed/37885772
http://dx.doi.org/10.1016/j.jvacx.2023.100359

Ejemplares similares